Skip to content

Clinical trials

Multiple Endocrine Neoplasia Type 1 trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Endocrine Neoplasia Type 1 Phase: Not applicable Country / region: United States Clear all

32 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20081
20093
20102
20112
20122
20142
20152
20172
20185
20192
20202
20211
20221
20243
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Unknown status3
Active, not recruiting2
Enrolling by invitation1
Recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Arizona State University4
Florida State University2
State University of New York - Downstate Medical Center2
Albert Einstein College of Medicine1
Charles Drew University of Medicine and Science1
Elidah, Inc.1
Fertility Centers of Illinois1
Georgetown University1
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center1
Michigan State University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Endocrine Neoplasia Type 132
Obesity4
Weight Loss4
Acquired Immunodeficiency Syndrome2
Diabetes Mellitus, Type 22
HIV Infections2
Overweight2
Sexually Transmitted Diseases2
Bone Diseases, Metabolic1
Breast Neoplasms1

Trials

Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.